Patents by Inventor Christopher Springate

Christopher Springate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110250275
    Abstract: Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent.
    Type: Application
    Filed: April 12, 2011
    Publication date: October 13, 2011
    Applicant: ARC MEDICAL DEVICES, INC.
    Inventors: JOHANNE CASHMAN, CHRISTOPHER SPRINGATE, CHARLES WINTERNITZ
  • Publication number: 20110104295
    Abstract: Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 5, 2011
    Applicant: ARC MEDICAL DEVICES, INC.
    Inventors: JOHANNE CASHMAN, CHRISTOPHER SPRINGATE, CHARLES WINTERNITZ
  • Publication number: 20080063682
    Abstract: Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent.
    Type: Application
    Filed: March 23, 2007
    Publication date: March 13, 2008
    Inventors: Johanne Cashman, Christopher Springate, Charles Winternitz
  • Publication number: 20040224914
    Abstract: A therapeutic method for treatment of non-cancerous angiogenesis-related diseases involves administering a therapeutically effective amount of a composition effective to reduce the effective amount of clusterin in the individual. Preferred therapeutic compositions contain antisense oligonucleotides which reduce the effective amount of clusterin.
    Type: Application
    Filed: April 19, 2004
    Publication date: November 11, 2004
    Applicant: The University of British Columbia
    Inventors: John K. Jackson, Helen Burt, Christopher Springate, Martin Gleave
  • Publication number: 20040220131
    Abstract: Cancerous angiogenesis-related diseases treated, and angiogenesis is reduced by administration of a therapeutically effective amount of a composition effective to reduce the effective amount of clusterin in an individual. Preferred therapeutic compositions comprise antisense oligonucleotides which reduce the effective amount of clusterin.
    Type: Application
    Filed: April 19, 2004
    Publication date: November 4, 2004
    Applicant: The University of British Columbia
    Inventors: John K. Jackson, Helen Burt, Christopher Springate, Martin Gleave
  • Publication number: 20030134811
    Abstract: Compositions and methods for in vivo delivery of pharmaceutically active agents associated with hydroxyapatite (HAP). Compositions comprising a pharmacologically active agent and HAP in a pharmaceutically acceptable carrier, the composition providing controlled release of the pharmacologically active agent when introduced into the body. The pharmaceutically acceptable carrier can be a polymer paste or gel which may contain a second pharmacologically active agent. Methods of making and administering a controlled release compositions for the delivery of a pharmacologically active agent, such as a nucleic acid, in combination with a polycationic polymer and in a pharmaceutically acceptable carrier, to a mammal in a pharmaceutically effective amount.
    Type: Application
    Filed: September 26, 2002
    Publication date: July 17, 2003
    Inventors: John Jackson, Christopher Springate, Wesley Wong, Helen M. Burt